Animalcare Group (ANCR) investor relations material

Strategic vision and growth trajectory

• Targeting GBP 150 million revenue by 2030, driven by organic growth, innovation, and M&A, with a balanced approach across all pillars.

• Transitioned from a fragmented, highly leveraged business to a focused, growth-oriented platform with reduced debt and a streamlined portfolio by end of 2025.

• Top 10 products now drive organic growth, with gross margin rising from 56% to 65% and owned/licensed products comprising 95% of revenue.

• Strategic investments in sales force, commercial excellence, and dental channel expansion underpin near-term growth.

• Geographic expansion prioritized in France, Italy, Germany, Australia, New Zealand, and the U.S., with M&A firepower of GBP 20-25 million and openness to equity raises.

Commercial excellence and operational improvements

• Enhanced commercial capabilities deliver revenue growth 2% higher and earnings growth 5% higher than peers.

• Unified CRM and harmonized processes implemented, enabling data-driven decision-making and scalable growth.

• Germany case study shows 35% growth in Daxocox and 21% in Plaqtiv+ through disciplined execution.

• Sales force expansion and onboarding initiatives forecast to deliver incremental EBITDA from 2027.

• Manufacturing network optimization underway, targeting full completion by 2029 to improve supply performance and capacity.

Multi-channel and innovation-driven expansion

• Focus on expanding the dental franchise into online and omni-channel retail, aiming for 20% CAGR in OTC portfolio over five years.

• Rights to all channels in Europe for Plaqtiv+ and global rights for Orozyme position the business for significant dental revenue growth by 2030.

• Conservative, pay-for-performance approach to online retail expansion to avoid cannibalizing core vet channel.

• R&D investment focused on cross-species drug discovery, with a lean, flexible operational model and robust risk management.

• Pipeline includes proprietary pharmaceuticals and biologics, with NPD contributing from 2029 and transformational growth expected post-2030.